Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · CIPLA

CIPLA LTD.

HealthcarePharmaceuticals & Biotechnology₹115190 cr market cap
₹1418.50 ▲ +0.11% today As of 19 Nov 2026
52-week low ₹1192.4052-week high ₹1535.60

-7.7% from the 52-week high · +18.8% above the low

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. The company is headquartered in Mumbai, Maharashtra and currently employs 26,615 full-time employees. The firm operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The firm's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The firm's geographical segments include India, the United States, South Africa, and Rest of the World. The firm has its network of manufacturing, trading and other incidental operations in India and International markets. The firm has approximately 47 manufacturing sites.

The short version. CIPLA LTD. reported revenue of ₹7,404 crore for Sep 2026, down 2.4% from a year earlier. Net profit was ₹878 crore (down 35.0% year on year). Return on equity was 11.3% in Mar 2026. Promoter holding was 29.2% in Sep 2026, up 0.01 points over 8 quarters.

1 · The price

How has the stock traded?

CIPLA LTD. trades 7.7% below its 52-week high and 18.8% above its 52-week low.

Change over period: —

1M+7.0%
3M-0.4%
6M+1.3%
1Y-6.4%

2 · The business

Is it growing?

Sales, year on year-2.4%

Sep 2026 revenue of ₹7,404 cr.

Profit, year on year-35.0%

Sep 2026 net profit of ₹878 cr.

Net margin11.9%

5.9 pts lower than a year earlier.

3-year growth11.5% profit

Revenue compounded at 7.7% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue74047119654170747589695767307073
Net profit8787895556761351129812221571
Net margin %11.911.18.59.617.818.718.222.2
EPS (₹)10.869.776.878.3716.7316.0615.1319.45

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue2816327548257742275321763191601713216362
Net profit38795273412228022517240515471528
Net margin %13.819.116.012.311.612.69.09.3
EPS (₹)48.0265.2851.0534.7131.1929.8219.1818.96

3 · The quality

How well does it turn capital into profit?

Return on equity was 11.3% in Mar 2026; debt to equity is 0.01.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %11.316.915.412.0
Return on capital %14.921.621.117.0
EBITDA margin %22.328.125.822.9
Net margin %13.418.615.512.1

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR7.7%8.4%
Profit CAGR11.5%10.0%
Debt to equity0.01
Interest cover97.0x
Current ratio3.44

4 · The owners

Who holds it, and are they adding?

Promoter holding29.2%

Up 0.01 pts over 8 quarters.

Foreign institutions20.25%

Down 6.4 pts over 8 quarters.

Domestic institutions34.94%

Up 7.23 pts over 8 quarters.

Mutual fund schemes344

+72 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter29.1929.229.1929.2229.2229.2229.2229.2+0.01
FII26.6526.2825.2524.5523.9322.5620.2120.25-6.4
DII27.7128.1529.2630.2530.7231.9734.6334.94+7.23
Public16.4416.3716.315.9916.1316.2515.9415.6-0.84

Mutual fund holdings · Oct 2026

344 schemes hold this stock

272 the month before.

  • ICICI Prudential Nifty Pharma ETF7.67% of NAV
  • Nippon India Nifty Pharma ETF7.67% of NAV
  • ICICI Prudential Nifty Pharma Index Fund7.67% of NAV
  • DSP Healthcare Fund7.4% of NAV
  • Bandhan Healthcare Fund7.21% of NAV
  • ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND7.1% of NAV
  • ICICI Prudential Nifty Healthcare ETF6.73% of NAV
  • DSP Nifty Healthcare ETF6.73% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for CIPLA LTD. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about CIPLA LTD.

What is the CIPLA LTD. share price?

CIPLA LTD. (CIPLA) last closed at ₹1,418.50, up 0.11% on the day. Its 52-week range is ₹1,192.40 to ₹1,535.60.

What is the market cap of CIPLA LTD.?

CIPLA LTD. has a market capitalisation of about ₹115,190 crore.

How are CIPLA LTD.'s latest results?

CIPLA LTD. reported revenue of ₹7,404 crore for Sep 2026, down 2.4% from a year earlier. Net profit was ₹878 crore (down 35.0% year on year). Return on equity was 11.3% in Mar 2026. Promoter holding was 29.2% in Sep 2026, up 0.01 points over 8 quarters.

Who owns CIPLA LTD.?

As of Sep 2026, shareholding was: Promoter 29.2%, FII 20.25%, DII 34.94%, Public 15.6%.

How many mutual funds hold CIPLA LTD.?

344 mutual fund schemes held CIPLA LTD. in October 2026. That compares with 272 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 05 Jun 2026 · Final Dividend - Rs. 13
  • 27 Jun 2025 · Special Dividend - Rs. 3
  • 27 Jun 2025 · Final Dividend - Rs. 13
  • 02 Aug 2024 · Final Dividend - Rs. 13
  • 21 Jul 2023 · Final Dividend - Rs. 8.5
  • 08 Aug 2022 · Dividend - Rs. 5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.